Genomic Alterations in Lung and Thyroid Cancer: Expert Guidance in Incorporating Molecular Testing to Deliver Precision Therapy

In this multidisciplinary online program experts provide guidance on the optimal management of lung or thyroid cancer with a genomic aberration in NTRK or RET from testing to treatment. Watch on-demand webcasts of live meetings featuring the perspectives of medical oncologists pathologists and endocrinologists and then download the corresponding slides along with an accompanying clinical resource PDF for use in your clinic.

Share

Program Content

Activities

Thyroid Cancer: Biomarker Testing
Overview, Rationale, and Guidance on Testing for Rare Genomic Alterations in Advanced Thyroid Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 13, 2022

Lung Cancer: Biomarker Testing
Overview, Rationale, and Guidance on Testing for Rare Genomic Fusions in NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 14, 2022

Activities

Lung and Thyroid Cancer: Mol Alterations
Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 17, 2022

Lung and Thyroid Testing
Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 10, 2023

Expires: April 09, 2024

Activities

Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know
Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: January 04, 2023

Endocrinology Perspective
Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know
Video
Congratulations: You achieved a completion on 04/09/2022

Released: March 15, 2023

Expires: March 14, 2024

Activities

<em>RET</em> and <em>NTRK</em> Aberrations
RET and NTRK Genomic Aberrations in Lung and Thyroid Cancer: A Resource for Healthcare Professionals
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: November 14, 2022

Faculty

cover img faculity

Maria E. Cabanillas, MD

Professor
Department of Endocrine Neoplasia and Hormonal Disorders
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Juan C. Hernandez-Prera, MD

Associate Member
Department of Pathology
Section Head
Head & Neck - Endocrine Pathology
Department of Pathology
Moffitt Cancer Center
Tampa, Florida

cover img faculity

Saad A Khan, MD

Leader Endocrine Cancer Research Group
Associate Professor of Medicine (Oncology)
Stanford University
Stanford Cancer Institute
Stanford, California

cover img faculity

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

cover img faculity

Jeremy P. Segal, MD, PhD

Associate Professor
Department of Pathology
Director
Molecular and Cytogenetic Pathology
University of Chicago
Chicago, Illinois

cover img faculity

Lori J. Wirth, MD

Associate Professor
Medical Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc, Blueprint Medicines and Genentech, a member of the Roche Group, and Lilly.

Bayer HealthCare Pharmaceuticals Inc.

Blueprint Medicines and Genentech, a member of the Roche Group

Lilly

Partners

American Society for Clinical Pathology

ProCE Banner

Partnered with the American Society for Clinical Pathology.